BRAF and central nervous system cancer: Our group demonstrated significant anti-tumor efficacy of PLX4720 (tool compound analog of the BRAFV600E-specific inhibitor vemurafenib) in intracranial xenografts harboring BRAFV600E-mutant gliomas, while showing no efficacy against BRAF-wild type xenografts [9].